Trial Profile
A retrospective study to evaluate the prognostic and predictive value of Systemic immune-inflammation in patients with metastatic renal cell cancer treated with sunitinib
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Apr 2016
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Pharmacodynamics; Therapeutic Use
- 01 Apr 2016 New trial record